详细说明
- Purity>70%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain at 5 μg per lane
- Endotoxin Level<1.0 EU per 1 μg of the protein by the LAL method.
- ActivityMeasured by the cleavage of the substrate GFPuv/SNAP/VAMP in a gel-shift assay. >40% of 1 μg substrate is cleaved by 800 ng, as measured under the described conditions. See Activity Assay Protocol on www.RnDSystems.com
- SourceE. coli-derived Pro2-Asn428, with an N-terminal Met and 6-His tag
- Accession #
- N-terminal Sequence
AnalysisHis - Predicted Molecular Mass50 kDa
- SDS-PAGE44-47 kDa, reducing conditions
| 7379-ZN | | |
| Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl, Tween® and Glycerol. | ||
| Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. | ||
| Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Assay Procedure
Materials
- Assay Buffer: 50 mM HEPES, 20 µM ZnCl2, pH 6.5
- Recombinant C. botulinum BoNT‑C1 Light Chain (rBoNT/C1-LC) (Catalog # 7379-ZN)
- Substrate: Recombinant GFP/SNAP25B/VAMP-2 (Catalog # )
- SDS-PAGE and silver stain reagents or equivalent or Western blot with appropriate antibodies
- Dilute Substrate to 100 µg/mL in Assay Buffer.
- Dilute rBoNT/C1-LC to 80 µg/mL in Assay Buffer.
- Combine equal volumes of diluted Substrate with diluted rBoNT/C1-LC. Prepare two controls by combining equal volumes of diluted Substrate with Assay Buffer.
- Incubate reaction vials 37 °C for 4 hours. Incubate one control at 37 °C and the other at -20 °C for 4 hours.
- After incubation, combine reaction mixtures and controls with reducing SDS-PAGE sample buffer at a 1:1 (reaction mixture:sample buffer) ratio (v/v) to stop reactions.
- Analyze the cleavage products by SDS-PAGE (Load 40 µL of the mixture from step 5 per lane, 1 µg Substrate per lane) followed by silver staining and/or Western blot.
- rBoNT/C1-LC: 800 ng
- Substrate: 1 µg
Background: BoNT-C1 Light Chain
Botulinum Neurotoxin Type C1 is one of the seven serotypes of Botulinum Neurotoxins (BoNTs) produced by various strains of Clostridium botulinum (1, 2). BoNTs are synthesized as inactive single chain protein precursors that are activated by proteolytic cleavage to create the light and heavy chains that are linked by a disulfide bond. The 50 kDa light chain contains the metalloprotease domain whereas the 100 kDa heavy chain contains a receptor binding domain and a domain required for translocation across the cell membrane (3). BoNTs are the most toxic protein toxins known for humans. As zinc proteases, they cleave SNARE proteins to elicit flaccid paralysis in botulism poisoning. Cleavage of the SNARE proteins results in the blocking of acetylcholine release at the neuromuscular junction (2‑4). E. coli expressed recombinant light chains are active proteases. In the absence of heavy chains, however, they lack toxicity because they cannot enter into host cells.
- References:
- Campbell, K.D. et al. (1993) J. Clin. Microbiol. 31:2255.
- Montecucco, C. and S. Giampietro (1993) Trends Biochem. Sci. 18:324.
- Turton, K. et al. (2002) Trends Biochem. Sci. 27:552.
- Schiavo, G. et al. (2000) Physiol. Rev. 80:717.
- Long Name:Botulinum Neurotoxin Type C1 Light Chain
- Alternate Names:BoNTC1 Light Chain; BoNT-C1 Light Chain
400-6226-992